Search - tctmd.com

Displaying 1 - 20 of 48

Sort: Relevancy | Date

News Daily News

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

L.A. McKeown

February 14, 2025

News Opinion CV Team Dispatch

February 2025 Dispatch for the CV Team

L.A. McKeown

February 01, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

L.A. McKeown

February 23, 2024

News Daily News

Low Bleeding Profile With Asundexian Seen in Pooled Analysis

L.A. McKeown

February 13, 2024

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

L.A. McKeown

November 20, 2023

Presentation AHA 2023

The Artesia trial: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Presenter: Jeff Healey

November 16, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

L.A. McKeown

August 30, 2023

News Daily News

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

L.A. McKeown

December 16, 2022

News Daily News

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

L.A. McKeown

January 20, 2022

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

Todd Neale

December 27, 2021

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

Shelley Wood

October 15, 2021

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

Caitlin E. Cox

June 25, 2020

News Daily News

FDA Approves Two Generic Versions of Apixaban

Todd Neale

December 23, 2019

News Daily News

NOACs Significantly Curb Risk of VTE in Cancer Patients

L.A. McKeown

December 06, 2018

News Daily News

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

L.A. McKeown

January 02, 2018

News Daily News

Blood in Urine Carries Consequences for Patients on Antithrombotics

Yael L. Maxwell

October 09, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

Shelley Wood

September 30, 2017

Advertisement

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

February 2025 Dispatch for the CV Team

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

Low Bleeding Profile With Asundexian Seen in Pooled Analysis

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

The Artesia trial: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

FDA Approves Two Generic Versions of Apixaban

NOACs Significantly Curb Risk of VTE in Cancer Patients

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

Blood in Urine Carries Consequences for Patients on Antithrombotics

TCTMD’s Top 10 Most Popular Stories for September 2017

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content